Premium
Innovative personalized medicine in gastric cancer: time to move forward
Author(s) -
Lee J.,
Kim K.M.,
Kang W.K.,
Ou S.H.I.
Publication year - 2014
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/cge.12408
Subject(s) - trastuzumab , targeted therapy , medicine , oncology , cancer , precision medicine , personalized medicine , human epidermal growth factor receptor 2 , clinical trial , population , chemotherapy , epidermal growth factor receptor , bioinformatics , biology , pathology , breast cancer , environmental health
Globally, gastric cancer ( GC ) is the second leading cancer cause of death. To date, only one targeted therapy trial generated positive survival outcomes in a selected population among many targeted therapy trials. This trial showed the addition of trastuzumab to fluoropyrimidine/platinum chemotherapy as first‐line chemotherapy for human epidermal growth factor receptor 2 ( HER2 )‐positive GC that resulted in an overall survival (OS) benefit. The increasing use of next generation sequencing approach to genomically profile GC patients allows the identification of many more GC patients who could benefit from specific targeted agents. Here we provide a comprehensive review of targeted therapy trials in GC and discuss future potential actionable driver mutations in GC .